News Release originally published at SmartBrief

A private placement of about 1.28 million new registered shares could bring in approximately $6.5 million for Berlin-based molecular diagnostic company Epigenomics. The net proceeds will be used for current operations, as well as to support US commercial expansion for its colorectal cancer screening test, Epi proColon.

See the entire news release.